HAB Pharma expands presence with new Dehradun facility, advancing healthcare innovation

HAB Pharmaceutical & Research Ltd, a leading pharmaceutical manufacturer, has acquired a 10-acre plot in Dehradun, formerly owned by Elder Pharmaceuticals Ltd, as part of its ambitious expansion strategy. This strategic move aims to strengthen HAB Pharma’s manufacturing capabilities and meet the growing demand in the healthcare sector.
Established in 1989 by entrepreneurs KK Agrawal and Sanjiv Garg, the company has grown into an industry powerhouse, renowned for its innovation, high-speed production lines, and robust manufacturing processes. With a diverse portfolio that includes trusted products like Nu Turboderm and Multi 9 tablets, HAB Pharma continues to be a preferred partner for major pharmaceutical companies.
The company shares that the newly acquired Dehradun site will house a state-of-the-art Metered Dose Inhaler (MDI) manufacturing facility, addressing the growing demand for respiratory treatments. Additionally, the company is venturing into biologics, with a focus on treatments for autoimmune disorders, a rapidly expanding segment in advanced healthcare solutions.
HAB Pharma currently operates two world-class facilities — one in Vasai, Mumbai, and another in Dehradun. Its sister concern, Signature Phytochemical, further strengthens its manufacturing presence with three units in Dehradun, including dedicated facilities for specialized pharmaceutical production. The recent launch of a state-of-the-art beta-lactam injectable facility enhances the company’s capabilities, reinforcing its commitment to quality and innovation.

Renowned for its commitment to quality and efficiency, HAB Pharma is a trusted contract manufacturer for leading pharmaceutical companies such as Zydus Lifesciences and Alkem Laboratories. The company’s ability to deliver high-quality products at scale has solidified its position as a key player in the global pharmaceutical supply chain.
HAB Pharma’s dedicated formulation development team continuously works on new product innovations, supported by rigorous bioequivalence studies to ensure optimal efficacy. The company’s investments in formulations with enhanced bioavailability further reinforce its focus on delivering effective healthcare solutions.
With its latest expansion, HAB Pharma is poised to redefine pharmaceutical manufacturing in India and beyond. The company's commitment to innovation, quality, and patient well-being continues to drive its mission of advancing global healthcare standards.
Disclaimer - The above content is non-editorial, and TIL hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.